Organon (OGN) Total Non-Current Liabilities (2020 - 2026)
Organon (OGN) posted quarterly Total Non-Current Liabilities of $11.1 billion for Q1 2026, down 4.4% year-over-year from $11.6 billion in Q1 2025, and little changed on a QoQ basis from $11.1 billion in Q4 2025.
Organon (OGN) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
Organon (OGN) has reported Total Non-Current Liabilities for 7 consecutive years, with $11.1 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 4.4% year-over-year to $11.1 billion; the TTM figure through Mar 2026 stood at $11.1 billion (down 4.4% YoY), while the FY2025 annual figure was $11.1 billion, down 4.68% from the prior year.
- Total Non-Current Liabilities came in at $11.1 billion for Q1 2026 at Organon, roughly flat from $11.1 billion in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $11.7 billion in Q4 2023, with the low at $11.1 billion in Q3 2022.
- Average Total Non-Current Liabilities over 5 years is $11.4 billion, with a median of $11.4 billion recorded in 2022.
- The largest YoY upside for Total Non-Current Liabilities was 270.75% in 2022 against a maximum downside of 11.13% in 2022.
- Year by year, Total Non-Current Liabilities stood at $11.4 billion in 2022, then gained by 2.45% to $11.7 billion in 2023, then dropped by 0.55% to $11.7 billion in 2024, then slipped by 4.68% to $11.1 billion in 2025, then rose by 0.02% to $11.1 billion in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $11.1 billion, $11.1 billion, and $11.5 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 48.74 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 119.22 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 109.01 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -34.06 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 75.17 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 80.55 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 31.56 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 113.51 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | 100.00 Mn |
| 10 | Organon | 3.53 Bn | 2.41 Bn | 783.00 Mn | 11.11 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.11 Bn |
| Dec 31, 2025 | 11.11 Bn |
| Sep 30, 2025 | 11.52 Bn |
| Jun 30, 2025 | 11.65 Bn |
| Mar 31, 2025 | 11.62 Bn |
| Dec 31, 2024 | 11.65 Bn |
| Sep 30, 2024 | 11.59 Bn |
| Jun 30, 2024 | 11.46 Bn |
| Mar 31, 2024 | 11.29 Bn |
| Dec 31, 2023 | 11.72 Bn |
| Sep 30, 2023 | 11.18 Bn |
| Jun 30, 2023 | 11.14 Bn |
| Mar 31, 2023 | 11.08 Bn |
| Dec 31, 2022 | 11.44 Bn |
| Sep 30, 2022 | 11.06 Bn |
| Jun 30, 2022 | 11.30 Bn |
| Mar 31, 2022 | 11.39 Bn |
| Dec 31, 2021 | 11.73 Bn |
| Sep 30, 2021 | 12.45 Bn |
| Jun 30, 2021 | 12.36 Bn |